Cytosorbents (CTSO) Long-Term Deferred Tax (2020 - 2021)
Cytosorbents posted quarterly Long-Term Deferred Tax of $35.3 million for Q4 2021, up 8083.57% year-on-year from $431490.0 in Q4 2020, and up 8083.57% on a QoQ basis from $431490.0 in Q4 2020.
Cytosorbents (CTSO) has 2 years of Long-Term Deferred Tax data on file, last reported at $35.3 million in Q4 2021.
- For the quarter ending Q4 2021, Long-Term Deferred Tax rose 8083.57% year-over-year to $35.3 million; the trailing twelve-month figure through Dec 2021 stood at $35.3 million (up 8083.57% YoY), and the FY2021 full-year result was $35.3 million, up 8083.57% from the prior year.
- Long-Term Deferred Tax for Q4 2021 stood at $35.3 million, up from $431490.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $35.3 million in Q4 2021 and bottomed at $431490.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 35.31 Mn |
| Dec 31, 2020 | 431,490.00 |